TY - JOUR
T1 - Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC
AU - Glazer, Chad A.
AU - Smith, Ian M.
AU - Ochs, Michael F.
AU - Begum, Shahnaz
AU - Westra, William
AU - Chang, Steven S.
AU - Sun, Wenyue
AU - Bhan, Sheetal
AU - Khan, Zubair
AU - Ahrendt, Steven
AU - Califano, Joseph A.
PY - 2009
Y1 - 2009
N2 - Background: Cancer/testis antigens (CTAs) were first discovered as immunogenic targets normally expressed in germline cells, but differentially expressed in a variety of human cancers. In this study, we used an integrative epigenetic screening approach to identify coordinately expressed genes in human non-small cell lung cancer (NSCLC) whose transcription is driven by promoter demethylation. Methodology/Principal Findings: Our screening approach found 290 significant genes from the over 47,000 transcripts incorporated in the Affymetrix Human Genome U133 Plus 2.0 expression array. Of the top 55 candidates, 10 showed both differential overexpression and promoter region hypomethylation in NSCLC. Surprisingly, 6 of the 10 genes discovered by this approach were CTAs. Using a separate cohort of primary tumor and normal tissue, we validated NSCLC promoter hypomethylation and increased expression by quantitative RT-PCR for all 10 genes. We noted significant, coordinated coexpression of multiple target genes, as well as coordinated promoter demethylation, in a large set of individual tumors that was associated with the SCC subtype of NSCLC. In addition, we identified 2 novel target genes that exhibited growth- promoting effects in multiple cell lines. Conclusions/Significance: Coordinated promoter demethylation in NSCLC is associated with aberrant expression of CTAs and potential, novel candidate protooncogenes that can be identified using integrative discovery techniques. These findings have significant implications for discovery of novel CTAs and CT antigen directed immunotherapy.
AB - Background: Cancer/testis antigens (CTAs) were first discovered as immunogenic targets normally expressed in germline cells, but differentially expressed in a variety of human cancers. In this study, we used an integrative epigenetic screening approach to identify coordinately expressed genes in human non-small cell lung cancer (NSCLC) whose transcription is driven by promoter demethylation. Methodology/Principal Findings: Our screening approach found 290 significant genes from the over 47,000 transcripts incorporated in the Affymetrix Human Genome U133 Plus 2.0 expression array. Of the top 55 candidates, 10 showed both differential overexpression and promoter region hypomethylation in NSCLC. Surprisingly, 6 of the 10 genes discovered by this approach were CTAs. Using a separate cohort of primary tumor and normal tissue, we validated NSCLC promoter hypomethylation and increased expression by quantitative RT-PCR for all 10 genes. We noted significant, coordinated coexpression of multiple target genes, as well as coordinated promoter demethylation, in a large set of individual tumors that was associated with the SCC subtype of NSCLC. In addition, we identified 2 novel target genes that exhibited growth- promoting effects in multiple cell lines. Conclusions/Significance: Coordinated promoter demethylation in NSCLC is associated with aberrant expression of CTAs and potential, novel candidate protooncogenes that can be identified using integrative discovery techniques. These findings have significant implications for discovery of novel CTAs and CT antigen directed immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=77949515989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949515989&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0008189
DO - 10.1371/journal.pone.0008189
M3 - Article
C2 - 19997593
AN - SCOPUS:77949515989
SN - 1932-6203
VL - 4
JO - PLoS One
JF - PLoS One
IS - 12
M1 - e8189
ER -